Mario Gabelli's BSX Position Overview
Mario Gabelli (via Gamco Investors, Inc. Et Al) currently holds 155,146 shares of Boston Scientific Corporation (BSX) worth $9.74 M, representing 0.10% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 52 quarters.
Based on 13F filings since 2013, Mario Gabelli has maintained a long-term strategic position in BSX, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2024, adding 58,861 shares. Largest reduction occurred in Q2 2015, reducing 354,500 shares.
Analysis based on 13F filings available since 2013 Q2
Mario Gabelli's Boston Scientific Corporation (BSX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Boston Scientific Corporation (BSX) Trades by Mario Gabelli
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +43,507 | Add 38.97% | 155,146 | $62.75 |
| Q4 2025 | -12,353 | Reduce 9.96% | 111,639 | $95.35 |
| Q3 2025 | -1,207 | Reduce 0.96% | 123,992 | $97.63 |
| Q2 2025 | -1,383 | Reduce 1.09% | 125,199 | $107.41 |
| Q1 2025 | -2,743 | Reduce 2.12% | 126,582 | $100.88 |
| Q4 2024 | +9,035 | Add 7.51% | 129,325 | $89.32 |
| Q3 2024 | +16,966 | Add 16.42% | 120,290 | $83.80 |
| Q2 2024 | +58,861 | Add 132.38% | 103,324 | $77.01 |
| Q1 2024 | -5,150 | Reduce 10.38% | 44,463 | $68.49 |
| Q4 2023 | -3,100 | Reduce 5.88% | 49,613 | $57.81 |
| Q3 2023 | -6,660 | Reduce 11.22% | 52,713 | $52.80 |
| Q2 2023 | -4,500 | Reduce 7.05% | 59,373 | $54.09 |
| Q1 2023 | -2,700 | Reduce 4.06% | 63,873 | $50.03 |
| Q4 2022 | -3,100 | Reduce 4.45% | 66,573 | $46.27 |
| Q3 2022 | -1,800 | Reduce 2.52% | 69,673 | $38.72 |
| Q2 2022 | +400 | Add 0.56% | 71,473 | $37.27 |
| Q1 2022 | -9,710 | Reduce 12.02% | 71,073 | $44.29 |
| Q4 2021 | +2,500 | Add 3.19% | 80,783 | $42.48 |
| Q3 2021 | +10,165 | Add 14.92% | 78,283 | $43.39 |
| Q2 2021 | -280 | Reduce 0.41% | 68,118 | $42.76 |
| Q1 2021 | -3,250 | Reduce 4.54% | 68,398 | $38.66 |
| Q4 2020 | -7,100 | Reduce 9.02% | 71,648 | $35.95 |
| Q3 2020 | -5,683 | Reduce 6.73% | 78,748 | $38.21 |
| Q2 2020 | -18,900 | Reduce 18.29% | 84,431 | $35.11 |
| Q1 2020 | -17,450 | Reduce 14.45% | 103,331 | $32.63 |
| Q4 2019 | -40,333 | Reduce 25.03% | 120,781 | $45.22 |
| Q3 2019 | -15,700 | Reduce 8.88% | 161,114 | $40.69 |
| Q2 2019 | -33,500 | Reduce 15.93% | 176,814 | $42.98 |
| Q1 2019 | -16,900 | Reduce 7.44% | 210,314 | $38.38 |
| Q4 2018 | -10,550 | Reduce 4.44% | 227,214 | $35.34 |
| Q3 2018 | -74,300 | Reduce 23.81% | 237,764 | $38.50 |
| Q2 2018 | -19,345 | Reduce 5.84% | 312,064 | $32.70 |
| Q1 2018 | -121,500 | Reduce 26.83% | 331,409 | $27.32 |
| Q4 2017 | -74,950 | Reduce 14.20% | 452,909 | $24.79 |
| Q3 2017 | -23,200 | Reduce 4.21% | 527,859 | $29.17 |
| Q2 2017 | -74,500 | Reduce 11.91% | 551,059 | $27.72 |
| Q1 2017 | -27,587 | Reduce 4.22% | 625,559 | $24.87 |
| Q4 2016 | -19,900 | Reduce 2.96% | 653,146 | $21.63 |
| Q3 2016 | -14,700 | Reduce 2.14% | 673,046 | $23.80 |
| Q2 2016 | -108,300 | Reduce 13.60% | 687,746 | $23.37 |
| Q1 2016 | -25,700 | Reduce 3.13% | 796,046 | $18.81 |
| Q4 2015 | -25,100 | Reduce 2.96% | 821,746 | $18.44 |
| Q3 2015 | -116,450 | Reduce 12.09% | 846,846 | $16.41 |
| Q2 2015 | -354,500 | Reduce 26.90% | 963,296 | $17.70 |
| Q1 2015 | -332,650 | Reduce 20.16% | 1.32 M | $17.75 |
| Q4 2014 | -53,590 | Reduce 3.14% | 1.65 M | $13.25 |
| Q3 2014 | -81,800 | Reduce 4.58% | 1.7 M | $11.81 |
| Q2 2014 | -313,169 | Reduce 14.92% | 1.79 M | $12.77 |
| Q1 2014 | -102,300 | Reduce 4.65% | 2.1 M | $13.52 |
| Q4 2013 | -33,600 | Reduce 1.50% | 2.2 M | $12.02 |
| Q3 2013 | -304,600 | Reduce 11.99% | 2.23 M | $11.74 |
| Q2 2013 | +2.54 M | Add 0.00% | 2.54 M | $9.27 |
Mario Gabelli's Boston Scientific Corporation Investment FAQs
Mario Gabelli first purchased Boston Scientific Corporation (BSX) in Q2 2013, acquiring 2,539,505 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Mario Gabelli has held Boston Scientific Corporation (BSX) for 52 quarters since Q2 2013.
Mario Gabelli's largest addition to Boston Scientific Corporation (BSX) was in Q2 2013, adding 2,539,505 shares worth $23.54 M.
According to the latest 13F filing for Q1 2026, Mario Gabelli's firm, Gamco Investors, Inc. Et Al, owns 155,146 shares of Boston Scientific Corporation (BSX), valued at approximately $9.74 M.
As of the Q1 2026 filing, Boston Scientific Corporation (BSX) represents approximately 0.10% of Mario Gabelli's publicly disclosed stock portfolio, making it one of their key holdings.
Mario Gabelli's peak holding in Boston Scientific Corporation (BSX) was 2,539,505 shares, as reported at the end of Q2 2013.